Waldenström's Macroglobulinemia

Anita D'Souza, Morie A. Gertz

Research output: Chapter in Book/Report/Conference proceedingChapter


This chapter presents a series of multiple choice questions and answers and case studies on Waldenström's macroglobulinemia (WM). It commences with a discourse on WM. The chapter talks about the genetic changes associated with WM, response to treatment measured, and different standard and novel therapies in WM. It analyzes whether autologous stem cell transplantation should be a front-line option. The chapter concludes with a discussion on cryoglobulinemia and related autoimmune disorders in WM. Risk of amyloid light-chain (AL) amyloidosis, immunoglobulin M (IgM)-related neurologic manifestations and survivorship issues in W4M are also discussed.

Original languageEnglish (US)
Title of host publicationCancer Consult
Subtitle of host publicationExpertise for Clinical Practice
Number of pages5
ISBN (Electronic)9781118589199
ISBN (Print)9781118589212
StatePublished - Jun 20 2014


  • Allogeneic stem cell transplantation
  • Amyloid light-chain (AL) amyloidosis
  • Autologous stem cell transplantation
  • Cryoglobulinemia
  • W4M
  • Waldenström's macroglobulinemia (WM)

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Waldenström's Macroglobulinemia'. Together they form a unique fingerprint.

Cite this